GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Hepatology

Topics

Medicine

Epidemiology

Internal Medicine

Hepatology

Hepatitis Delta

Show all topics

DOI

10.1016/s0168-8278(24)00425-2